Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $51.90.

Several analysts have recently issued reports on TWST shares. Wolfe Research started coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Scotiabank increased their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Robert W. Baird increased their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Finally, Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 4,160 shares of Twist Bioscience stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $185,536.00. Following the completion of the sale, the chief financial officer now owns 89,237 shares in the company, valued at $3,979,970.20. This trade represents a 4.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Dennis Cho sold 659 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $27,388.04. Following the completion of the transaction, the insider now owns 94,481 shares in the company, valued at $3,926,630.36. This represents a 0.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 89,801 shares of company stock worth $4,147,858 over the last 90 days. Company insiders own 3.01% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience in the 3rd quarter worth $34,000. Van ECK Associates Corp lifted its stake in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares during the period. Signaturefd LLC lifted its stake in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the period. Beaird Harris Wealth Management LLC bought a new position in Twist Bioscience during the 3rd quarter worth about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares during the period.

Twist Bioscience Trading Up 2.4 %

Shares of TWST stock opened at $52.37 on Friday. The stock’s 50-day moving average price is $48.39 and its 200-day moving average price is $46.30. Twist Bioscience has a 12-month low of $27.41 and a 12-month high of $60.90. The stock has a market capitalization of $3.11 billion, a price-to-earnings ratio of -14.55 and a beta of 1.85.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.